scholarly journals Recombinant Human Growth Hormone Inhibits Lipotoxicity, Oxidative Stress, and Apoptosis in a Mouse Model of Diabetic Cardiomyopathy

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Zuowei Pei ◽  
Xiang Wang ◽  
Chenguang Yang ◽  
Min Dong ◽  
Fang Wang
Keyword(s):  
Oxidative Stress ◽  
Growth Hormone ◽  
Cardiac Function ◽  
Human Growth Hormone ◽  
Diabetic Cardiomyopathy ◽  
Recombinant Human Growth Hormone ◽  
Fasting Blood Glucose ◽  
Human Growth ◽  
Protective Effects ◽  
Rhgh Treatment

Recombinant human growth hormone (rhGH), widely used in clinical studies, exerts protective effects against cardiac damage. Here, we investigated the effects and mechanisms underlying the effects of rhGH on cardiac functions in db/db mice. C57BL/6J and db/db mice were subjected to rhGH treatment. Metabolic parameters, cardiac function and morphology, oxidative stress, lipid metabolism, and apoptosis were evaluated 16 weeks after rhGH treatment. Although rhGH did not significantly affect fasting blood glucose levels in db/db mice, it protected against diabetic cardiomyopathy, by improving cardiac function and reducing oxidative stress in the heart. In addition, rhGH treatment exhibited anti-apoptotic effects in the heart of db/db mice. The rhGH treatment, besides inhibiting oxidative stress and apoptosis, ameliorated cardiac dysfunction by inhibiting lipotoxicity in mice with type 2 diabetes. These findings suggest that rhGH is a promising therapeutic agent for diabetic cardiomyopathy.

The Angle of Trunk Rotation in Children With Growth Hormone Deficiency

2020 ◽  
Author(s):  
Magdalena Kobylińska ◽  
Roksana Ewa Malak ◽  
Katarzyna Majewska ◽  
Włodzimierz Samborski ◽  
Andrzej Kędzia
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Human Growth Hormone ◽  
Bone Structure ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Deficiency ◽  
Trunk Rotation ◽  
Sport Activities ◽  
Rhgh Treatment

Abstract Background. Growth hormone plays a vital role in the human body. Its deficiency can lead to numerous disorders, including musculoskeletal system defects. Treatment with recombinant human growth hormone (rhGH) in children suffering from growth hormone deficiency (GHD) increases muscle mass and improves bone structure.Aim. The purpose of this study was to evaluate the angle of trunk rotation (ATR) in patients diagnosed with GHD treated with rhGH and to observe the incidence of scoliosis.Material and Methods. The study was conducted among 50 children diagnosed with GHD. The group consisted of 11 girls and 39 boys aged 6-16. The study group included 50 children: 10 children just qualified for rhGH treatment and 40 patients undergoing this treatment, with different therapy duration. ATR was measured using a Bunnell scoliometer on five levels of the spine: cervical 7 / thoracic 1, thoracic 6, thoracic 12 / lumbar 1, lumbar 3, lumbar 5 / sacral 1.Results. The most numerous asymmetries among the examined group were in the thoracolumbar segment and at the thoracic 6 level. Girls had greater asymmetries compared to boys especially at thoraco – lumbar and lumbar 3 level. There were no statistically significant differences in ATR at any level comparing patients before hormonal treatment and patients undergoing rhGH treatment. The age of the beginning of the therapy, the duration of rhGH therapy, and body mass index (BMI) also had no effect on ATR. Sport activities had a positive impact on the results obtained by scoliometer assessment.Conclusions. The angle of trunk rotation is higher in growth hormone-deficient females than in males. Weight, height, BMI, the time of growth hormone therapy beginning and the duration of this therapy do not influence ATR. The more sport activities, the lower value of the angle of trunk rotation, especially in male patients. Obtained results support the thesis, that treatment with recombinant human growth hormone does not increase the incidence of scoliosis.

scholarly journals Growth after recombinant human growth hormone (rhGH) treatment in transplanted thalassemic patients

1997 ◽  
Vol 20 (7) ◽  
pp. 567-573 ◽  
Author(s):  
M De Simone ◽  
PDi Bartolomeo ◽  
P Olioso ◽  
GDi Girolamo ◽  
M Palumbo ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Rhgh Treatment

scholarly journals The Use and Abuse of Human Growth Hormone in Sports

2018 ◽  
Vol 10 (5) ◽  
pp. 419-426 ◽  
Author(s):  
David M. Siebert ◽  
Ashwin L. Rao
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Sports Medicine ◽  
Gh Deficiency ◽  
Adult Population ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Level Of Evidence ◽  
Therapeutic Benefits ◽  
Rhgh Treatment

Context: Recombinant human growth hormone (rHGH) has become a target of abuse in the sporting world. Conversely, sports medicine clinicians may encounter athletes using rHGH to achieve normalcy in the context of growth hormone (GH) deficiency. Evidence Acquisition: Medline and PubMed databases were queried using the following keywords: GH, GH physiology, GH deficiency, acromegaly, GH athlete, GH sports, GH athletic performance, and GH deficiency concussion. Articles focusing on GH physiology, deficiency, excess, and its effects in both deficient and healthy patients were included. Study Design: Clinical review. Level of Evidence: Level 3. Results: GH is a naturally occurring hormone with important roles in human physiology. Patients with GH deficiency (GHD) present variably, and GHD has numerous etiologies. rHGH treatment has substantial therapeutic benefits for patients with GHD. The benefits of rHGH treatment in otherwise-healthy adults are uncertain. GH excess may cause health problems such as acromegaly. Professional, collegiate, and international sports leagues and associations have banned rHGH use to maintain athlete health, safety, and fair play. Athletes misusing GH may face prolonged suspensions from competition. Implementing GH abuse testing is challenging, but new methods, such as the biomarker testing procedure, are being finalized. Conclusion: rHGH is not only an important therapeutic agent for GH-deficient patients but also a target of abuse in competitive athletics. Its benefits in a healthy, adult population are uncertain. A safe exercise and competition plan, developed with a physician knowledgeable of GH use, physiology, and abuse potential, should be of benefit to a longitudinal clinician-patient relationship.

Recombinant human growth hormone (rhGH) treatment in children

Nephrology ◽  
2005 ◽  
Vol 10 (s5) ◽  
pp. S224-S230
Author(s):  
Charles Crompton
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Rhgh Treatment

scholarly journals Recombinant human growth hormone (rhGH) treatment of MKN-45 xenograft mice improves nutrition status and strengthens immune function without promoting tumor growth

PLoS ONE ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. e0210613
Author(s):  
Lianping Wei ◽  
Jianrong Chang ◽  
Zhen Han ◽  
Ronghai Wang ◽  
Lihua Song
Keyword(s):  
Growth Hormone ◽  
Tumor Growth ◽  
Immune Function ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Nutrition Status ◽  
Xenograft Mice ◽  
Rhgh Treatment

scholarly journals Association of thyroid autoimmunity and the response to recombinant human growth hormone in Turner syndrome

2020 ◽  
Author(s):  
Yuyao Song ◽  
Hongbo Yang ◽  
Linjie Wang ◽  
Fengying Gong ◽  
Hui Pan ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Turner Syndrome ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Thyroid Autoimmunity ◽  
Human Growth ◽  
Height Velocity ◽  
Thyroid Autoantibodies ◽  
Thyroid Autoantibody ◽  
Rhgh Treatment

Introduction: Short stature and thyroid autoimmunity are among the most common traits in Turner syndrome (TS). Recombinant human growth hormone (rhGH) treatment benefits height growth in Turner syndrome individuals when applicable. This study aims to investigate the association of thyroid autoimmunity and the response to rhGH treatment in Turner Syndrome patients. Methods: Medical records of 494 patients with TS were reviewed. Among 126 patients who regularly tested for thyroid autoantibodies, 108 patients had received rhGH treatment. Clinical characteristics, including karyotype and the presence of autoimmune thyroid diseases, as well as rhGH treatment records were analyzed. Height velocity (HV) of patients with or without thyroid autoimmunity was compared to assess the response to rhGH treatment. For patients who received rhGH treatment and positive for thyroid autoantibodies, height velocity before and after antibody presence was compared. Results: 45XO monosomy presented in 36% (176/496) of patients. 42.1% of patients (53/126) had elevated circulating anti-thyroid peroxidase antibody (TPOAb) and anti-thyroglobulin antibody (TgAb). In 108 patients who received rhGH treatment, a negative correlation was found between circulating TPOAb concentration and HV (n=53, r = -0.276, P<0.05). For patients who developed thyroid autoantibodies during rhGH treatment, HVs after thyroid autoantibody presence significantly decreased compared with HVs before thyroid autoantibody detection (n=44, p=0.0017). Conclusions: Our data suggested that in preadult TS patients who developed thyroid autoantibodies during rhGH treatment, the response to rhGH is negatively associated with the development of thyroid autoimmunity.

scholarly journals A Child with Local Lipohypertrophy following Recombinant Human Growth Hormone Administration

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Ilan J. N. Koppen ◽  
Roel Bakx ◽  
Chris C. de Kruiff ◽  
A. S. Paul van Trotsenburg
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Subcutaneous Fat ◽  
Human Growth ◽  
Asymmetric Distribution ◽  
Growth Hormone Insensitivity ◽  
One Year ◽  
Subcutaneous Fat Tissue ◽  
Rhgh Treatment

Local lipohypertrophy due to recombinant human growth hormone (rhGH) administration is a rare phenomenon. Here, we report a case of an 11-year-old girl who presented with a paraumbilical swelling, approximately one year after the start of rhGH treatment for short stature due to the presumed diagnosis of partial growth hormone insensitivity. Ultrasound imaging revealed an asymmetric distribution of subcutaneous fat tissue at the rhGH administration site, indicating local lipohypertrophy. After sparing her routine injection site and alternating other sites, the swelling disappeared within 6 months. Although the precise cause of local lipohypertrophy resulting from rhGH administration is still unclear, it might be related to the presumed diagnosis of partial growth hormone insensitivity.

Sign in / Sign up

Export Citation Format

Share Document